Sells ZYNLONTA, a targeted cancer medicine for relapsed or refractory large B-cell lymphoma, to healthcare providers and hospitals, and develops other antibody-drug conjugate medicines.
10-K for FY2025, filed Mar 10, 2026ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for…View ↗
In addition to the current approved product and pipeline above, IND-enabling activities for ADCT-241 (the Company’s exatecan-based…View ↗
We continue to directly commercialize ZYNLONTA in the 3L+ DLBCL setting in the United States through a commercial organization comprised of…View ↗
Most revenue comes from U.S. ZYNLONTA sales through wholesale distributors, with product revenue counted when the product transfers to the customer. Outside the U.S., partners provide upfront and milestone license payments and royalties; license fees may be earned at once or over time.
10-K for FY2025, filed Mar 10, 2026We generate product revenue through the sale of ZYNLONTA in the United States. Revenue is recognized when control is transferred to the…View ↗
We generate license revenue and royalties from our strategic agreements for the development and commercialization of ZYNLONTA outside of…View ↗
The Company recognizes revenues from license fees for intellectual property (IP) either at a point in time or over time. The Company must…View ↗
10-K for FY2025, filed Mar 10, 2026
FY2025 revenue by product or service ↗$81.4M
10-K for FY2025, filed Mar 10, 2026
$81.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenues, net
Sold outright
10-K for FY2025, filed Mar 10, 2026 |
90%
FY2022: 36%
|
Product revenues, net, FY2025
$73.6M Sources
|
Sold outright |
|
License revenues
Licensed
|
6.2%
FY2022: 64%
|
License revenues, FY2025
$5M Sources
|
Licensed |
|
Royalties
Licensed
|
3.5%
FY2022: 0.0%
|
Royalties, FY2025
$2.8M Sources
|
Licensed |
The U.S. sales team calls on healthcare providers, while wholesale distributors resell ZYNLONTA to providers and hospitals; outside the U.S., licensing partners and a joint venture handle commercialization.
10-K for FY2025, filed Mar 10, 2026
No. It lost $142.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$25.3MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
Continued progress toward potential commercialization of ZYNLONTA in Japan. ADC Therapeutics’ Japanese licensing partner, Tanabe Pharma…View ↗
Growing. Revenue grew 2.4x in 4 years, from $33.9M in FY2021 to $81.4M in FY2025, about 24% a year.
A narrower development focus
The earlier report described a broader pipeline of PBD-based candidates and plans to broaden the ADC platform. The latest report focuses resources on ZYNLONTA expansion and an exatecan-based PSMA-targeting candidate.
20-F for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 10, 2026
Competes with AbbVie, Daiichi Sankyo, Genmab, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Mersana Therapeutics, Sanofi, Roche Holding, Pfizer, and Zymeworks
10-K for FY2025, filed Mar 10, 2026Many companies are active in the oncology market and are developing or marketing products for the specific therapeutic markets that we…View ↗
Loading...